Outcome of 127 JMML patients according to prognostic methylation score divided into tertiles. (A) Probability of survival from diagnosis irrespective of disease status. Patients alive at last follow-up were censored. Death was considered the event. Numbers indicate the probability of 5-year survival and the 95% CI. (B) Probability of DFS in 97 JMML patients who had received HSCT. Numbers indicate the probability of 5-year DFS and the 95% CI. DFS was defined as the probability of being alive and disease-free. Patients alive and disease-free at last follow-up were censored. Death and relapse were considered the events. (C) Cumulative incidence of relapse of 97 patients who had received HSCT. Numbers indicate the 5-year cumulative incidence of relapse and the 95% CI. Relapse incidence was defined as the probability of JMML relapse at a given time. Death without relapse was considered a competing event.